Literature DB >> 34164774

Circular RNA circ-CHI3L1.2 modulates cisplatin resistance of osteosarcoma cells via the miR-340-5p/LPAATβ axis.

Zehua Zhang1, Qiang Zhou2, Fei Luo1, Rui Zhou1, Jianzhong Xu1, Jun Xiao1, Fei Dai3, Lei Song4.   

Abstract

Resistance to chemotherapy drugs is a major factor affecting the surgical outcome and prognosis of osteosarcoma patients. Circular RNAs (circRNAs) play an important role in tumor resistance to chemotherapy. In the present study, we aimed to investigate the role and mechanism of circRNA circ-chitinase 3-like 1.2 (CHI3L1.2) in resistance to cisplatin chemotherapy in osteosarcoma. We found that circ-CHI3L1.2 levels were higher in cisplatin-resistant cells than in their parent cells. circ-CHI3L1.2 knockdown decreased the half-maximal inhibitory concentration (IC50) of cisplatin and the expression levels of P-glycoprotein (P-gp), multidrug-resistance protein 1 (MRP1), and glutathione-S-transferase Pi1 (GSTP1), and promoted apoptosis of cisplatin-resistant osteosarcoma cells. In addition, circ-CHI3L1.2 knockdown induced mesenchymal to epithelial transition (MET) and suppressed cell migration and invasion. The competitive endogenous RNA (ceRNA) mechanism indicated that circ-CHI3L1.2 targets the micro-RNA (miR)-340-5p-lysophosphatidic acid acyltransferase β (LPAATβ) axis, and inhibition of miR-340-5p alleviates the effect of circ-CHI3L1.2 knockdown. In conclusion, circ-CHI3L1.2 levels were increased in cisplatin-resistant osteosarcoma cells and circ-CHI3L1.2 knockdown sensitized cisplatin-resistant osteosarcoma cells to cisplatin through the miR-340-5p-LPAATβ axis.
© 2021. Japan Human Cell Society.

Entities:  

Keywords:  Circ-CHI3L1.2; Cisplatin resistance; Competitive endogenous RNA; LPAATβ; miR-340-5p

Mesh:

Substances:

Year:  2021        PMID: 34164774     DOI: 10.1007/s13577-021-00564-6

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  17 in total

Review 1.  The understanding of circular RNAs as special triggers in carcinogenesis.

Authors:  Zhuoyuan Xin; Qin Ma; Shuangchun Ren; Guoqing Wang; Fan Li
Journal:  Brief Funct Genomics       Date:  2017-03-01       Impact factor: 4.241

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

Review 3.  Current and future therapeutic approaches for osteosarcoma.

Authors:  Douglas J Harrison; David S Geller; Jonathan D Gill; Valerae O Lewis; Richard Gorlick
Journal:  Expert Rev Anticancer Ther       Date:  2017-12-14       Impact factor: 4.512

4.  Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p.

Authors:  Lei Song; Zhigang Zhou; Yibo Gan; Pei Li; Yuan Xu; Zehua Zhang; Fei Luo; Jianzhong Xu; Qiang Zhou; Fei Dai
Journal:  J Cell Biochem       Date:  2018-12-11       Impact factor: 4.429

5.  Silencing LPAATβ inhibits tumor growth of cisplatin-resistant human osteosarcoma in vivo and in vitro.

Authors:  Lei Song; Ping Duan; Yibo Gan; Pei Li; Chen Zhao; Jianzhong Xu; Zehua Zhang; Qiang Zhou
Journal:  Int J Oncol       Date:  2016-12-28       Impact factor: 5.650

Review 6.  [Cisplatin resistance in a murine leukemia cell line associated with defect of apoptosis].

Authors:  E Segal-Bendirdjian; A Jacquemin-Sablon
Journal:  Bull Cancer       Date:  1996-05       Impact factor: 1.276

Review 7.  Relationship Between Noncoding RNA Dysregulation and Epigenetic Mechanisms in Cancer.

Authors:  Hiromu Suzuki; Reo Maruyama; Eiichiro Yamamoto; Takeshi Niinuma; Masahiro Kai
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

8.  Microarray profile of circular RNAs identifies hsa_circ_0014130 as a new circular RNA biomarker in non-small cell lung cancer.

Authors:  Shaoyan Zhang; Xiaoli Zeng; Ting Ding; Lin Guo; Yulong Li; Songlei Ou; Hui Yuan
Journal:  Sci Rep       Date:  2018-02-13       Impact factor: 4.379

9.  Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.

Authors:  Bernhard Robl; Chantal Pauli; Sander Martijn Botter; Beata Bode-Lesniewska; Bruno Fuchs
Journal:  BMC Cancer       Date:  2015-05-09       Impact factor: 4.430

10.  Circular RNAs function as competing endogenous RNAs in multiple types of cancer.

Authors:  Qing Ji; Chengcheng Zhang; Xiaoting Sun; Qi Li
Journal:  Oncol Lett       Date:  2017-11-03       Impact factor: 2.967

View more
  4 in total

1.  miR-340-5p mediates the therapeutic effect of mesenchymal stem cells on corneal neovascularization.

Authors:  Jian Pan; Xu Luo; Shujue Zhao; Jianmin Li; Zipei Jiang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-09-08       Impact factor: 3.535

2.  Circular RNA circ-PLCD1 functions as a tumor suppressor in non-small cell lung cancer by inactivation of PI3K/AKT signaling pathway.

Authors:  Jiming Si; Jianjun Jin; Jingjing Sai; Xiaoting Liu; Xiao Luo; Zhenqiang Fu; Jing Wang
Journal:  Hum Cell       Date:  2022-03-17       Impact factor: 4.374

Review 3.  The Role of Circular RNAs in the Drug Resistance of Cancers.

Authors:  Xin-Yuan Liu; Qi Zhang; Jing Guo; Peng Zhang; Hua Liu; Zi-Bin Tian; Cui-Ping Zhang; Xiao-Yu Li
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

Review 4.  An overview of resistance to chemotherapy in osteosarcoma and future perspectives.

Authors:  Dorian Yarih Garcia-Ortega; Sara Aileen Cabrera-Nieto; Haydee Sarai Caro-Sánchez; Marlid Cruz-Ramos
Journal:  Cancer Drug Resist       Date:  2022-06-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.